Comparison of different treatment regimens for the emergence of new resistance under therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 27, Issue 4, 2001, Pages 331-335

  Roberts, Daniel E ^a   Ribeiro, Ruy M ^b  

^a FLORIDA STATE UNIVERSITY   (United States)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

Antiretroviral therapy; Genotypic testing; HIV drug resistance; HIV quasispecies; Mathematical models; Treatment efficacy

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS MUTANT; VIRUS REPLICATION;

EID: 0035424617     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200108010-00002     Document Type: Article

References (33)

1. HIV treatment failure: Testing for HIV resistance in clinical practice
2. Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance
3. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors
4. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
5. HIV-1 drug resistance in newly infected individuals
6. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use
7. Transmission and prevalence of HIV resistance among treatment-naive subjects
8. Antiretroviral drug resistance testing in adult HIV-1 infection
9. Drug resistance genotyping in HIV-1 therapy
10. World wide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type I reverse transcriptase
11. Factors associated with the successful modification of antiretroviral therapy
12. A randomised study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
13. Limits of resistance testing
14. Clinical utility of testing human immunodeficiency virus for drug resistance
15. Tracker trials: Introduction of resistance testing might be an innapropriate use of resources
16. Principles of HIV resistance testing and overview of assay performance characteristics
17. Efficiency of drug resistance genotypic tests in specimens with low HIV viral load
18. Virus dynamics and drug therapy
19. Pre-existence and emergence of drug resistance in HIV-1 infection
20. Production of resistant HIV mutants during antiretroviral therapy
21. The concept of R0 in epidemic theory
22. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy
23. Presence of genotypic resistance in nucleoside analogue-treated HIV-1-infected patients with undetectable viral load
24. Antiretroviral resistance during successful therapy of HIV type 1 infection
25. Reduction of HIV concentration during acute infection: Independence from a specific immune response
26. Target cell limited and immune control models of HIV infection: A comparison
27. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
28. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
29. Viral dynamics of acute HIV-1 infection
30. Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection